World Health Organization Issues Warning Over Severe Lack of Obesity Injections
Less than a tenth of patients who could benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it releases its initial recommendations on the drugs.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is urging more widespread and fairer access to these injectable treatments.
According to estimates, more than two billion will be obese by 2030 without intervention.
"The latest guidelines affirms that excess weight is a chronic disease that can be managed with comprehensive and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key barriers to universal availability to the treatments that can help people shift considerable weight, says the body.
GLP-1 Therapy Supply Crisis
Despite the present most optimistic outlook, the manufacturing of such drugs could only cover about 100 million people – fewer than 10% of the global need, according to the WHO.
The recommendation encourages countries and companies to expand access, via measures such as licensing agreements.
A patent on semaglutide – the core component of Novo Nordisk's Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Work
These medications mimick a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so people reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of commencing the weekly injections.
Studies suggests users may regain a significant portion after a year of halting the medication, as their typical hunger come back.
To be carrying excess weight increases your likelihood for contracting medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Obesity impacts individuals in all nations and was responsible for millions of deaths worldwide in 2024, according to the health agency.